头孢呋辛酯与头孢克洛对照治疗下呼吸道感染的疗效观察

Randomized controlled clinical trial of cefuroxime axetil vs cefaclor in treatment of lower respiratory tract infection

目的:评价头孢呋辛酯与头孢克洛随机对照治疗下呼吸道感染的疗效和安全性。方法:轻、中度下呼吸道感染患者78例随机分成2组,头孢呋辛酯组(40例)予头孢呋辛酯500 mg,口服,2次/d;头孢克洛组(38例)予头孢克洛500 mg,口服,3次/d。2组均以7～14 d为1个疗程。结果:头孢呋辛酯组与头孢克洛组的临床有效率分别为92.5%与92.11%(P>0.05),细菌清除率为90.32%与89.66%(P>0.05),2组均无明显不良反应。结论:头孢呋辛酯可作为治疗轻、中度下呼吸道感染有效和安全的抗生素。

Objective： To evaluate the efficacy and safety of cefuroxime axetil in the treatment of lower respiratory tract infections. Methods： Seventy-eight patients with mild to moderate lower respiratory tract infection were divided into two groups. Fourty patients were treated with eefuroxime axetil 500 mg, orally, twice a day, Thirty-eight patients were treated with cefaclor 500 rag, orally, three times a day. In both groups 7-14 d was a treatment course. Results： The total clinical effective rates of cefuroxime axetil and cefaclor were 92.5 % and 92.11% （P〉0.05）, respectively. The bacterial clearance rates were 90. 32G and 89. 66% （P 〉0. 05）, respectively. Both groups showed no obvious adverse reactions. Conclusion： Cefuroxime axetil is a safe and potent antibacterial agent in treating mild to moderate lower respiratory tract infection.